FDA Approvals, Scheduled Presentations, and Stock Price Movements - Research Report on Amgen, St. Jude Medical, Life Technologies, Ligand, and Infinity Pharmaceuticals
29 Nov, 2013, 08:00 ET
NEW YORK, November 29, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Amgen, Inc. (NASDAQ: AMGN), St. Jude Medical, Inc. (NYSE: STJ), Life Technologies Corp. (NASDAQ: LIFE), Ligand Pharmaceuticals Inc. (NASDAQ: LGND), and Infinity Pharmaceuticals Inc. (NASDAQ:INFI). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Amgen, Inc. Research Report
On November 22, 2013, Onyx Pharmaceuticals, a subsidiary of Amgen, Inc. (Amgen), and Bayer Healthcare Pharmaceuticals Inc. together announced that the US Food and Drug Administration (FDA) approved a supplemental New Drug Application for the oral multi-kinase inhibitor NEXAVAR (sorafenib) tablets for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) refractor to radioactive iodine treatment. Amgen stated that the FDA approval is based on the results of the DECISION (stuDy of sorafEnib in loCally advanced or metastatIc patientS with radioactive Iodine refractory thyrOid caNcer) trial, an international, multicenter, placebo-controlled study. Commenting on the news, Pamela A. Cyrus, M.D., Vice President and Head of U.S. Medical Affairs, Bayer Healthcare Pharmaceuticals, stated, "Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment is difficult to treat. NEXAVAR is the first and only FDA-approved therapy for this type of thyroid cancer and is a positive development for patients who previously had limited treatment options." The Company informed that NEXAVAR was approved following a priority review by the FDA, a designation reserved for drugs that may offer a significant improvement in treatment over existing options.The Full Research Report on Amgen, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
St. Jude Medical, Inc. Research Report
On November 21, 2013, St. Jude Medical, Inc. (St. Jude Medical) announced that the Company will present at the Piper Jaffray 25th Annual Healthcare Conference on December 3, 2013, in New York City. The Company informed that Don Zurbay, Vice President, Finance and CFO will address the conference at 9:30 a.m. ET. St. Jude Medical stated that the live webcast of the presentation will be available at the Company website. The Full Research Report on St. Jude Medical, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Life Technologies Corp. Research Report
On November 26, 2013, Life Technologies Corp.'s (Life Technologies) stock rose 0.08%, ending the day at $75.75. Over the previous three trading sessions, shares of Life Technologies gained 0.16% compared to the Nasdaq Composite which gained 1.22% during the same period. The Full Research Report on Life Technologies Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Ligand Pharmaceuticals Inc. Research Report
On November 26, 2013, Ligand Pharmaceuticals Inc.'s (Ligand) stock rose 5.48%, ending the day at $57.75. Over the previous three trading sessions, shares of Ligand gained 11.08% compared to the Nasdaq Composite which gained 1.22% during the same period. The Full Research Report on Ligand Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Infinity Pharmaceuticals Inc. Research Report
Infinity Pharmaceuticals Inc. (Infinity Pharmaceuticals) posted the schedule of its upcoming conferences and events on the events section of its Company website. The Company stated that it will present at the Deutsche Bank BioFEST Conference in Boston, Massachusetts on December 2, 2013 at 10:10 a.m. ET, and will host ASH Investor Reception and Webcast, on December 8, 2013 at 12:00 p.m. ET. According to the Company, the webcast of the presentations will be available on the Events & Presentation section of the Company website. The Full Research Report on Infinity Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner
Share this article